ACP-105 Powder

Establishment of Pathological Models for Sarcopenia and Cachexia

ACP-105 powder serves as a standard reference agent for in vitro and in vivo experiments related to muscular atrophy. In castrated rat models, sustained administration can reverse muscle fiber atrophy induced by testosterone deficiency, upregulate the gene expression of actin and myosin, accelerate skeletal muscle protein synthesis, and suppress the ubiquitin-mediated protein degradation pathway. It is applied to mechanistic research on age-related sarcopenia, tumor cachexia, and muscle wasting caused by prolonged bed rest.

Compared with testosterone preparations, this powder does not trigger benign prostatic hyperplasia, enabling long-term construction of muscle wasting repair models free from visceral organ interference. It is widely adopted as a control drug for screening anti-atrophy peptides and antioxidant composite formulations, and compatible with activity verification tests for special medical nutritional formulas.

Research on Osteoporosis and Bone Metabolic Pathways

As an osteoblast-selective agonist, the powder enhances osteoblast activity, inhibits osteoclast differentiation, elevates the secretion of osteocalcin and type I collagen, and alleviates reduced bone mineral density and trabecular fractures in castrated animal subjects.

Devoid of the urogenital side effects associated with conventional androgens, it is frequently utilized in mechanistic studies on postmenopausal osteoporosis and prevention of age-related fragility fractures.

By comparing it with bisphosphonates and parathyroid peptide drugs, researchers analyze androgen receptor-mediated bone remodeling signaling pathways, supporting the screening of bone-targeted small-molecule lead compounds.

Model Experiments for Neuroprotection and Cognitive Impairment

Recent preclinical animal studies have validated the central neuromodulatory effects of ACP-105.

Dissolved powder can be administered to transgenic mice with Alzheimer's disease to mitigate hippocampal neuronal damage, improve spatial memory, alleviate radiation-induced motor neurodegeneration, and relieve anxiety behaviors accompanying hypogonadism.In scientific research, it is predominantly employed to investigate androgen-regulated neural plasticity, interventions for age-related cognitive decline, and repair mechanisms of radiation-induced brain injury, filling the experimental gap left by testosterone's unsuitability for long-term central nervous system administration.

Mechanistic Research on Body Composition Remodeling and Strength Enhancement

Within exercise science laboratories, the product is utilized in trials focusing on simultaneous fat loss and muscle gain (body recomposition). Its mild anabolic properties preserve lean muscle mass and reduce visceral fat accumulation under calorie deficit conditions without notable water retention, making it suitable for animal training models focused on lean muscle hypertrophy and body contour shaping.

When administered alongside resistance training, it boosts muscular endurance, explosive power and post-exercise recovery speed, shortening the repair cycle of minor muscle injuries. Researchers employ it to analyze the regulatory mechanisms of androgen receptors governing exercise adaptation, muscle glycogen storage and lactic acid metabolism, and use it as an activity control reference for novel sports nutrition raw materials.

Compatibility Experiments for Synergistic Composite Formulations

The powder exhibits excellent formulation compatibility and is frequently combined with growth hormone secretagogue MK-677, PPARδ agonist GW501516 (Cardarine), carnosine and branched-chain amino acids for combined administration research.

While standalone ACP-105 targets muscle and bone tissue, co-administration with other active ingredients concurrently improves sleep quality, fat oxidation and vascular endothelial health.

In research, it supports in vitro cellular and in vivo animal evaluations for developing compound sports nutrition powders and post-workout recovery agents. It is used to compare endocrine fluctuations triggered by different selective androgen receptor modulator (SARM) combinations, and to identify optimal blending ratios and administration cycles.

Research on Candidate Drugs for Hormone Deficiency Replacement in Middle-Aged and Elderly Populations

Testosterone replacement therapy carries risks of benign prostatic hyperplasia and dyslipidemia. As a tissue-selective candidate for hormone replacement, the product undergoes comprehensive preclinical assessment. It is administered to animal models of late-onset hypogonadism in aging males and muscle weakness in postmenopausal females to verify its efficacy in boosting physical performance, stabilizing mood and preserving bone mass.

Meanwhile, monitoring of prostate-specific antigen and estradiol levels enables comparison of safety profiles against traditional hormone therapies, generating data to support the development of low-side-effect androgen replacement lead compounds.

Research on Muscle Rehabilitation Models Post-Surgery and Post-Trauma

Prolonged immobilization following orthopedic surgery or severe trauma commonly leads to disuse muscular atrophy.

Administration of the product to immobilized animal models effectively slows muscle wasting during bed rest and accelerates strength recovery during rehabilitation training.

It is used to investigate synergistic effects of nutritional rehabilitation formulations and pharmacotherapy combined with physical rehabilitation after trauma, and to explore interactive regulatory pathways between androgen receptors and growth factors during muscle injury repair.

HNMR is the core method for confirming the chemical structure of ACP-105. By detecting the chemical shifts and coupling relationships of hydrogen atoms in a molecule, the positions of its molecular skeleton and functional groups can be precisely verified. For example, the molecular formula of ACP-105 is C16H19ClN2O. HNMR can clarify the signal characteristics of its benzene ring, chlorine atom, nitrogen heterocyclic and hydroxyl groups, etc.

Mass spectrometry is used to determine the molecular weight of ACP-105 and the information of its fragment ions. High-resolution mass spectrometry (HRMS) can precisely determine the molecular weight (290.79) and assist in verifying the molecular structure. For example, the CAS number of ACP-105 is 899821-23-9, and the mass spectrometry data can be exactly matched with its chemical formula.